Renal Denervation to Improve Outcomes in Patients With End-stage Renal Disease

Baker Heart and Diabetes Institute

Status

Completed

Conditions

Hypertension

End-stage Renal Disease

Treatments

Procedure: Renal Denervation

Study type

Interventional

Funder types

Other

Identifiers

NCT02021019

1052470 (Other Grant/Funding Number)

527/13

Details and patient eligibility

About

Sympathetic activation is a hallmark of end-stage renal disease and adversely affects cardiovascular prognosis. Hypertension is present in the vast majority of these patients and plays a key role in the progressive deterioration of renal function and in the exceedingly high rate of cardiovascular events. Selective catheter-based renal denervation has been shown to be safe and effective in attaining improved and sustained blood pressure control in patients with resistant hypertension and normal renal function. The investigators hypothesize that catheter-based renal denervation is a safe and effective intervention to achieve sustained reduction in sympathetic nerve activity, BP and target organ damage in hypertensive End-Stage Renal Disease (ESRD) patients, which will result in improved cardiovascular outcomes.

Enrollment

3 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

end stage renal disease
hypertension (BP≥140/90mmHg)

Exclusion criteria

Individual has renal artery anatomy that is ineligible for treatment as assessed by the interventionalist.
Individual has experienced a myocardial infarction, unstable angina, or a cerebrovascular accident within 3 months of the screening visit.